These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 1354676

  • 1. Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol.
    Aramaki T, Sekiyama T, Katsuta Y, Kurokawa H, Komeichi H, Tsutsui H, Terada H, Ohsuga M, Satomura K, Okumura H.
    J Hepatol; 1992 May; 15(1-2):48-53. PubMed ID: 1354676
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
    Bañares R, Moitinho E, Piqueras B, Casado M, García-Pagán JC, de Diego A, Bosch J.
    Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
    [Abstract] [Full Text] [Related]

  • 5. Hemodynamic effects of nipradilol, a new beta-adrenergic antagonist combined with a nitroxy base, in rats with intra- or extra-hepatic portal hypertension.
    Ohsuga M, Cailmail S, Lebrec D.
    J Hepatol; 1993 Feb; 17(2):236-40. PubMed ID: 8095275
    [Abstract] [Full Text] [Related]

  • 6. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study.
    Schepis F, Vukotic R, Berzigotti A, Carrión JA, Forns X, Abraldes JG, García-Valdecasas JC, Navasa M, García-Pagán JC, Bosch J.
    Liver Transpl; 2013 Apr; 19(4):450-6. PubMed ID: 23408436
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis.
    Forrest EH, Bouchier IA, Hayes PC.
    J Hepatol; 1996 Dec; 25(6):909-15. PubMed ID: 9007720
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cardiovascular effects of nipradilol, a beta-adrenoceptor blocker with vasodilating properties.
    Fujii M, Shirasawa Y, Kondo S, Sawanobori K, Nakamura M.
    Jpn Heart J; 1986 Mar; 27(2):233-50. PubMed ID: 2873263
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
    Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-Radosavljevic M, Vienna Hepatic Hemodynamic Lab.
    J Gastroenterol; 2012 May; 47(5):561-8. PubMed ID: 22170417
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.